Moleculaire beeldvorming van de oestrogeenreceptor dichtheid om de hormonale behandelingsmogelijkheden voor patiënten met borstkanker te verbeteren.
- Conditions
- breast cancer acquired anti-hormonal resistance
- Registration Number
- NL-OMON26431
- Lead Sponsor
- niversity Medical Center Groningen (UMCG), department of medical oncology
- Brief Summary
1. Dehdashti F, Mortimer JE, Trinkaus K. et al. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat (2009) 113:509-517;<br> 2. Ellis MJ, Dehdashti F, Kommareddy A et al. A randomized phase 2 trial of low dose (mg daily) versus high dose (30mg daily) estradiol for patients with estrogen receptor positive aromatase inhibitor resistant advanced breast cancer. Breast Cancer Symposium 2008 San Antonio.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 50
1. Patients with the diagnosis of acquired anti-hormonal resistant advanced breast cancer showing progression after two or more lines of antihormonal treatment;
2. Treatment with estradiol will be started;
1. Life Expectancy <3 months;
2. Uncontrolled CNS metastases;
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method With a ROC analysis we will determine the optimal sensitivity and specificity of FES-PET in relation with the standard uptake value (SUV) to predict response to estrogen therapy.
- Secondary Outcome Measures
Name Time Method 1) To discriminate the acquired anti-hormonal resistant phenotypes in patients based on ER expression levels by FES-PET;<br /><br>2) Correlation between SUV and response to therapy.